Burning Rock, Illumina to Co-Develop Molecular Diagnostics for Oncology

Chinese diagnostics company Burning Rock is partnering with Illumina to develop advanced clinical applications for cancer diagnostics.

Burning Rock will develop the applications based on San Diego-based Illumina’s next-generation sequencing technology. The plan is to develop a user-friendly, oncology molecular diagnostic kit for the Chinese market.

Illumina will contribute NGS technology instrument components and related reagents, and Burning Rock will provide its nucleic acid extraction, library preparation and data analysis software.

Burning Rock CEO Yusheng Han says the goal is to promote molecular diagnosis of cancers based on NGS as a standard practice in Chinese hospitals. — Michael Cipriano